Yissum, the Technology Transfer Company of The Hebrew University of Jerusalem, published this week its 2021 Portfolio of 15 promising new startups.
Follow Israel Hayom on Facebook, Twitter, and Instagram
Founded in 1964, Yissum (which means "implementation" in Hebrew) serves as a bridge between academic research and entrepreneurs, investors, and industry. Yissum has registered over 10,900 patents globally; licensed over 1,140 technologies and spun out more than 200 companies.
"Yissum has long been considered Israel's leading technology transfer company, but our recent successes along with the unprecedented level of portfolio companies, investment partners, and highly promising early-stage tech serve as a real-life testament to that fact," said Yissum CEO Dr. Itzik Goldwaser.
"While this group of startups shows promise when it comes to commercial success, they are also poised to change millions of lives and we will continue to help foster and scale these technologies in order to achieve their full potential," Goldwaser said.
The following companies are now part of Yissum's portfolio:
RNAWay, which has developed a platform to deliver siRNA to plants
Immunyx Pharma, which has developed technology relating to a platform to allow neutrophil-specific targeting, a mode of immunotherapy
Lipovac, a company developing a liposome-based vaccine to treat different illness indications including, but not limited to, viral infections such as COVID-19
ExoNavis Therapeutics, which is harnessing the exosome, an extracellular vesicle, as a multi-drug delivery vehicle
NexoCarp: Pickering solid dispersion and particles for the delivery of agents
PSYRX, which is developing tissue culture protocols to produce and isolate psilocybin and ibogaine psychedelic compounds in bioreactors for the treatment of various central nervous system diseases
MyComed Super Foods, which uses medicinal herbs and Spirulina Algae mixed in foods to improve skeletal quality and prevent osteoporosis
Cavos: Develops new diagnostic, prognostics, and treatment options for a wide array of diseases and conditions using different genomes with artificial intelligence (AI) and machine learning-based tools
Noga3D, which has developed epoxy-based 3D printing materials
I-Red Pharma, which offers novel treatment for diseases using new small and multi-property molecules (Superdopa and Superdopamide)
SOLRA, which has developed fully screen-printable Perovskite Solar Cells
Sea2Cell: A technology for raising cultured fish by growing fish cells in vitro
EverBlue Labs: Produces zero-discharge fish aquariums
Bountica: Anti-Fungal Peptides
RNABLE which has technology comprising a novel target for the treatment of rare genetic diseases and cancer caused by nonsense mutations
Subscribe to Israel Hayom's daily newsletter and never miss our top stories!
